Chemometec A/S
CSE:CHEMM

Watchlist Manager
Chemometec A/S Logo
Chemometec A/S
CSE:CHEMM
Watchlist
Price: 487.6 DKK -0.69% Market Closed
Market Cap: 8.5B DKK
Have any thoughts about
Chemometec A/S?
Write Note

Chemometec A/S
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Chemometec A/S
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Chemometec A/S
CSE:CHEMM
Income from Continuing Operations
kr136.3m
CAGR 3-Years
16%
CAGR 5-Years
27%
CAGR 10-Years
N/A
G
Gubra A/S
CSE:GUBRA
Income from Continuing Operations
-kr44.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Chemometec A/S
Glance View

Market Cap
8.5B DKK
Industry
Life Sciences Tools & Services

Chemometec A/S, a Danish firm founded in the late 1990s, has carved a niche in the specialized world of biotech instrumentation. The company is renowned for developing and manufacturing high-precision cell counting and analysis instruments used predominantly in the life sciences sector. Its flagship product, the NucleoCounter®, has gained significant traction in laboratories and production facilities worldwide. This product stands out due to its accuracy and ease of use in counting various types of cells, whether in research or pharmaceutical production settings. Unlike traditional methods, Chemometec’s technology enables researchers to save time and reduce error, which is invaluable for laboratories looking to enhance their workflow efficiencies. Revenue for Chemometec is primarily generated through the sale of its advanced instruments and associated consumables, along with providing expert services that support the integration and maintenance of these technologies. The company's business model capitalizes on the growing global demand for sophisticated biomedical research tools, as innovation in the drug development and biotechnology sectors accelerates. By continuously investing in R&D, Chemometec not only ensures its products remain cutting-edge but also expands its applicability across new areas in the life sciences field. The strategy of maintaining close relationships with its end-users ensures that as the scientific landscape evolves, Chemometec is well-positioned to adapt and grow.

CHEMM Intrinsic Value
324.51 DKK
Overvaluation 33%
Intrinsic Value
Price

See Also

What is Chemometec A/S's Income from Continuing Operations?
Income from Continuing Operations
136.3m DKK

Based on the financial report for Jun 30, 2024, Chemometec A/S's Income from Continuing Operations amounts to 136.3m DKK.

What is Chemometec A/S's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
27%

Over the last year, the Income from Continuing Operations growth was -24%. The average annual Income from Continuing Operations growth rates for Chemometec A/S have been 16% over the past three years , 27% over the past five years .

Back to Top